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lations, or comparable study arms preventing a complete assessment of whether 
sub-indications of an anti-diabetic drug provided an “added benefit” to patients. 
Future clinical development plans should include well-designed comparative stud-
ies to improve likelihood of reimbursement and patient access.
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Objectives: To estimate health-state utilities for adverse outcomes associated 
with metastatic colorectal cancer. MethOds: Patients and physicians completed 
time trade-off (TTO) questions. Health states were drafted and refined based on 
literature review, and patient and clinician interviews. Four adverse conditions 
were described: severe papulopustular rash (rash), serious bleeding, severe heart 
attack, and gastrointestinal perforations. Respondents evaluated the risk of serious 
bleeding, heart attack, and gastrointestinal perforation. Three event risk levels were 
randomized across events and respondents. Rash was presented as a deterministic 
outcome, so respondents evaluated the impact of experiencing the rash, not as a 
‘risk’ of developing rash. Patients and physicians evaluated the health states in 
TTO questions that provided a range of time in the adverse health that would leave 
respondents indifferent between the adverse health states and shorter life spans 
with perfect health. TTO data were analyzed using an interval regression model to 
estimate the health-state utility for each side effect. Results were used to infer the 
health-state utility of the outcomes’ clinically relevant levels corresponding with 
the most commonly used targeted treatments for mCRC, VEGFi and EGFRi (20% 
chance of rash, 5% chance of serious hemorrhage, and a 2% chance of gastrointes-
tinal perforations and cardiopulmonary arrest). Results: A total of 127 patients 
and 150 physicians completed the TTO questions. Among clinically-relevant levels 
of the health states for patients, cardiopulmonary arrest had the lowest utility 
(0.68), with serious hemorrhage (0.74), GI perforation (0.79) and rash (0.91) hav-
ing higher levels of utility. Utility scores for physicians followed a similar pattern: 
cardiopulmonary arrest (0.75), serious hemorrhage (0.76), GI perforation (0.82) and 
rash (0.92). CONClUSIONS: Results add to previously published literature regarding 
utilities for adverse outcomes from patients’ and physicians’ perspectives. Results 
show that patient and physician ratings of health states were largely consistent, 
suggesting agreement in the perceived impact of these adverse events.
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Objectives: Elicit medicine preferences of women eligible to receive first-line 
maintenance treatment for ovarian cancer and estimate benefit-risk trade-
offs. MethOds: Women in the United States with self-reported physician diag-
noses of ovarian cancer and eligible for maintenance therapy completed an online 
discrete-choice experiment (DCE) survey. The survey presented nine choice ques-
tions, each including a pair of hypothetical medicine profiles with varying effi-
cacy, tolerability, and risks of side effects. Each profile was defined by the following 
attributes identified from the literature with clinical input and tested in patient 
interviews: progression-free survival (PFS), fatigue, diarrhea, nausea and vomiting, 
hypertension, and risk of gastrointestinal (GI) perforation. The profiles in the choice 
questions were based on an experimental design with known statistical properties. 
Random-parameters logit was used to estimate preferences. Results: Two hundred 
women completed the survey; median age was 49 years, 26% were late stage (3/4), 
and 44% had been diagnosed within 2 years. Across the attributes, better outcomes 
were significantly preferred to worse outcomes, except that respondents did not 
distinguish between no nausea and mild nausea. Relative to the other attributes 
and levels, respondents placed the greatest weight on avoiding severe diarrhea, 
followed by reducing the risk of GI perforation, and increased PFS. Respondents 
were willing to give up 6.5 months of PFS to reduce diarrhea from severe to none. 
No statistical differences were found between the overall preferences of early versus 
late stage respondents, respondents above and below the median age in the sample, 
and respondents who had been diagnosed in the last 2 years compared to those 
diagnosed more than 2 years ago. cOnclusiOns: Women with ovarian cancer were 
willing to trade-off efficacy (PFS) for improvements in side effects and risk. The lack 
of differences across subgroups suggest consistent preferences across the attributes 
within our sample. Funded by GSK.
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Objectives: Relative preference weights for outcomes of anticoagulant therapy 
can be used to inform quantitative benefit-risk analyses. Whether patients with 
cardiovascular diseases (CVD) and the general population have different preferences 
for benefits and risks of anticoagulant therapy is unknown. Using a Discrete Choice 
Experiment (DCE), we elicited and compared anticoagulant treatment outcomes 
preferences between patients and the general population. MethOds: A sample of 
patients with CVD and a general US population sample were selected from online 
panels. A DCE questionnaire was designed and administered to elicit preferences 
for benefits and risks. Seven attributes described hypothetical treatments randomly 
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Objectives: Cost-effectiveness analysis (CEA) is explicitly used for informing drug 
coverage decisions in many countries but not in the United States. Evidence suggests 
that failure to incorporate value considerations in coverage decisions may lead to 
reduced economic efficiency in the form of increased costs or worsened health 
outcomes. Yet the use of CEA in the context of binary coverage decisions (yes or 
no) may not be politically or socially feasible in the US. In 2010, Premera Blue Cross 
implemented a value-based formulary (VBF) that uses CEA to determine the copay-
ment level-not binary coverage-for each drug in the formulary; drugs with lower 
incremental cost-effectiveness ratios (ICERs) are assigned lower copayments, drugs 
with higher ICERs are assigned higher copayments. The objective of this study is to 
assess the impact of Premera’s VBF on healthcare costs and outcomes. MethOds: 
We utilize an interrupted time series design with concurrent control group in order 
to examine the impact of the VBF on both pharmacy and medical costs for enrollees 
and the health plan separately and to examine the impact of the VBF on both emer-
gency department visits and acute hospitalizations. In order to accomplish these 
aims, we utilize segmented regression models with two-part generalized estimating 
equations for analysis. Results: Preliminary descriptive analysis suggests that over 
the 4 years of observation, comparing the period before VBF implementation to the 
period after VBF implementation, both medical and pharmacy costs increased more 
in the control group ($38.37 and $4.79 per member per month (PMPM)) than in the 
VBF group ($3.16 and -$0.54 PMPM). The number of emergency department visits and 
acute hospitalizations did not change in either group. cOnclusiOns: Preliminary 
analyses suggest that the use of cost-effectiveness principles in the US context may 
lead to greater economic efficiency. Subsequent analyses utilizing greater control for 
confounding will establish more valid estimates of outcomes and costs.
hT3
ANAlySIS OF NICE DRUG TEChNOlOGy APPRAISAlS (2001-SEPTEmBER 2014)
Briceno V, Seoane-Vazquez E
MCPHS University, Boston, MA, USA
Objectives: The UK National Institute for Health and Care Excellence (NICE) pro-
vides guidance and advice to improve health care in the UK. This study assessed 
the NICE Drug Technology Appraisals published in the period 2001-September 
2014. MethOds: The list of NICE guidance, including published guidance, in 
development and consultations was extracted from NICE webpage. Descriptive 
statistics and chi-square were used in the analysis. Results: In September 2014, 
NICE listed 994 guidance documents, including 246 technology appraisals (TA), of 
which 207 were drug TA. The drug TA assessed 158 different drugs, combinations, 
or drug classes. 75.8% of the drug TA evaluated was recommended by NICE in the 
National Health Service (NHS), however 17.0% of them were not recommended. NICE 
was unable to recommend them because no evidence submission was received 
from the drug sponsor in 7.2% of the TA. In 46.2% of the 91 TA published in 2010-
Sep 2014 and recommended by NICE, the sponsor agreed a patient access scheme 
with the Department of Health to provide a confidential discount. The percent-
age of TA resulting in drugs with indications recommended by NICE decreased 
over time from 89.5% (n= 49) in 2001-2004, to 71.7% (n= 91) in 2005-2009, and 75.8% 
in 2010-September 2014 (p< 0.001). There were six therapeutic classes with 10 or 
more TA: Cancer (68 TA, 57.4% recommended by NICE), blood and immune sys-
tem conditions (27, 77.8%), cardiovascular conditions (20, 95.0%), musculoskele-
tal conditions (16, 81.3%), infections (11, 90.9%), and neurological conditions (10, 
90.0%). cOnclusiOns: Most of the TA resulted in a positive recommendation by 
NICE for using the drug in the NHS. Oncology and blood and immune system condi-
tion had the lowest percentage of TA resulting in a positive evaluation from NICE. 
Over 45% of the TA published after 2010 resulted in a confidential discount provided 
by the sponsor company to the NHS.
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Objectives: Since 2011, the Institute for Quality and Efficiency in Health Care 
(IQWiG) has awarded very few anti-diabetic therapies an “added benefit” over 
current standard therapies status. IQWiG dossier evaluations were examined to 
determine if new therapies do not demonstrate “added benefit” or if results may 
be due to a lack of comparative evidence. MethOds: Results from IQWiG dossier 
assessments for all anti-diabetic drug therapies requiring early benefit assessment 
were examined. IQWiG’s website was searched for “diabetes,” identifying Albiglutide, 
Canagliflozin, Dapagliflozin, Empagliflozine, Linagliptin, Lixisenatide, Saxagliptin, 
Sitagliptin, and Vildagliptin. Dossier assessment results were reviewed for all sub-
indications to determine if added benefit had been evaluated. Results: In total, 14 
dossier assessments (9 monotherapies; 5 combination therapies) were reviewed rep-
resenting a total of 48 sub-indications. Of the 48 sub-indications, 2 were designated 
as having “added benefit” or “hint of added benefit,” the remaining 46 did not. The 
most common reasons for no evidence of “added benefit” were: no evidence sub-
mitted (n= 13) or evidence deemed irrelevant (n= 33). The most common reasons for 
supporting studies being deemed irrelevant included: differing “therapeutic strate-
gies” in study arms (n= 4); deviation from G-BA recommended comparator (n= 6); 
lack of power to demonstrate added benefit (n= 1); non-compliance with approved 
dosage (n= 12); non-compliance with approved population (n= 12); insulin therapy 
not tailored to patient (n= 6); study duration too short (n= 5). cOnclusiOns: In most 
cases, the evidence needed to perform an IQWiG early benefit assessment for drug 
therapies for Type II Diabetes did not exist. Moreover, studies with the potential to 
provide the appropriate evidence lacked use of approved dosage, indicated popu-
